Effect of Baseline Characteristics on Cabazitaxel Treatment Duration in Patients with Metastatic Castration-Resistant Prostate Cancer: A Post Hoc Analysis of the Compassionate Use/Expanded Access Programs and CAPRISTANA Registry

mCRPC; Cabazitaxel; CAPRISTANA

Bibliographic Details
Authors:	Malik, Zafar, Di Lorenzo, Giuseppe, Pichler, Angelika, Hitier, Simon, Ecstein-Fraisse, Evelyne, Carles Galceran, Joan, De Giorgi, Ugo
Format:	article
Status:	Published version
Publication Date:	2020
Country:	España
Institution:	Varias* (Consorci de Biblioteques Universitáries de Catalunya, Centre de Serveis Científics i Acadèmics de Catalunya)
Repository:	Recercat. Dipósit de la Recerca de Catalunya
OAI Identifier:	oai:recercat.cat:11351/6236
Online Access:	https://hdl.handle.net/11351/6236
Access Level:	Open access
Keyword:	Pròstata - Càncer Medicaments antineoplàstics - Ús terapèutic DISEASES::Neoplasms::Neoplasms by Site::Urogenital Neoplasms::Genital Neoplasms, Male::Prostatic Neoplasms::Prostatic Neoplasms, Castration-Resistant Other subheadings::Other subheadings::Other subheadings::/drug therapy ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias urogenitales::neoplasias de los genitales masculinos::neoplasias de la próstata::neoplasias prostáticas resistentes a la castración Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia

Description
Summary:	mCRPC; Cabazitaxel; CAPRISTANA